🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Dissecting the Molecular and Cellular Pathophysiology of Sarcopenic Obesity in the Elderly

Recruitingn/aAges 65 Years - 99 YearsAllIRCCS San Raffaele
NCT06320158 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Ageing is characterised by a change in body composition with a parallel decrease in muscle mass and an increase and central redistribution of fat. When drastically exacerbated, these two processes culminate in a condition known as sarcopenic obesity (SO). SO is characterised by the coexistence of obesity and sarcopenia (i.e. reduced muscle mass and function) and is a growing public health problem in the elderly. The health risks of obesity and sarcopenia act synergistically, maximising the risk of disability of OS. The molecular mechanisms underlying OS are largely unknown. Increased fat mass induces chronic systemic inflammation and alters the profiles of adipokines and hormones, promoting the development of sarcopenia. On the other hand, the reduction in muscle tissue (SM) typical of sarcopenia is characterised by an alteration in the metabolic properties of skeletal muscle with an inc

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: patients who are candidates for hip surgery * patients who are candidates for hip surgery * age ≥ 65 years * patients able to give consent healthy subjects \- healthy subjects from the geriatric cohort studied in 2016-2017 who at that time were: were overweight (25 ≤ BMI \< 30 kg/m2) or obese (BMI ≥ 30 kg/m2) but had not yet developed sarcopenia Exclusion Criteria: All partecipants * unavailability to participate in the study * inflammatory or neurological myopathies * acute heart failure * active cancer
💊

What it tests

  • clinical evaluation of sarcopenic obesity
📍

Where

1 site
Ospedale San Raffaele
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy